Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i> –Induced B-Cell Acute Lymphoblastic LeukemiaLinyu Yang, Lijuan Chen, Yuyao Yi et al.|Clinical Cancer Research|2019Cited by 19
Nanomedical Sonocatalyst Tailored for Enhanced Hypoxic Tumor Therapy Based on Crystal Facet Engineering StrategyMeng Yuan, Jun Lin, Zhuang Yang et al.|ACS Materials Letters|2024Cited by 4